TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05574712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment
Description: Each drug will be dosed at its respective FDA-approved dose. These dosages are as follows: leuprolide acetate 22.5 mg depot injection x one dose, abiraterone acetate 1000 mg by mouth daily, and belzutifan120 mg administered by mouth once daily. All men will also be treated with prednisone 5 mg by mouth twice daily while on abiraterone acetate in order to blunt its associated mineralocorticoid side effects
Study: NCT06406400

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine
Description: Participants with OUD will receive buprenorphine (as standard of care treatment) on Day 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine / Naloxone
Description: Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buprenorphine / Naloxone
Description: Participants with OUD will receive buprenorphine + naloxone (as standard of care treatment) on Days 4, 5, 6 and 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydromorphone
Description: Participants with OUD will receive hydromorphone (as a replacement opioid) on Days 1, 2 and 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1b: Healthy participants will receive matching placebo orally on Day 1 as a single dose.~Part 2: Participants with OUD will receive placebo daily from Days 1 to 7.
Study: NCT04771975

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Counselling
Description: Phase 1: See previous description for MatchQEP (Intervention) group. Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants had the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner. The 8-week program was open to all participants from Phase 1 who choose to continue in the study, regardless of initial randomization status. Behavioural and exercise counselling were offered to phase 2 participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partner Matching
Description: Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partner Matching
Description: Phase 1: All participants will be matched with another participant (fellow BCS) and will facilitate / support exercise with their partner for the duration of the study.~Phase 2: Was not an RCT (i.e., all Phase 1 participants were approached to participate in Phase 2). Phase 2 is a pre-post intervention design, with no control group. Phase 2 participants were rematched with different partner for this phase of the trial.~Participants will be matched based on personal and cancer-related characteristics.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance training sessions led by a QEP
Description: Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training sessions led by a QEP
Description: Phase 2: participants were offered the option to extend their time in the study for an additional 8-weeks, which includes an online virtual (zoom) resistance training program with a qualified exercise professional (QEP) with a new study partner.
Study: NCT06097455

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: ARI0003
Description: Treatment with ARI0003 cells
Study: NCT06548178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DXd
Description: T-DXd (5.4 mg/kg Q3W on Day 1) ×6 cycles.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: THP
Description: Docetaxel (75 mg/m2 Q3W on Day 1) concurrent with trastuzumab (8 mg/kg loading dose followed by 6 mg/kg Q3W on Day 1) and pertuzumab (840 mg loading dose followed by 420 mg Q3W on Day 1) × 6 cycles.
Study: NCT05070819

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pro-ANP
Description: pro-ANP samples and fluid status assessment with functional tests (Teboul test) will be used 8 times intraoperatively.
Study: NCT05608993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Intervention
Description: The High Intensity intervention will include clinician education, individualized clinician audit and feedback with peer comparison, and electronic health record (EHR) changes of prescription fields.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low Intensity Intervention
Description: The Low Intensity intervention will include clinician education and EHR changes only.
Study: NCT04830774

Intervention type: DEVICE
Group type: OTHER
Intervention: ILR, PMK, ICD
Description: * Patients receive a newly implanted ILR, PMK, or ICD during COVID-19 hospitalization or within 30 days after hospital discharge and are followed by daily automated remote transmissions.~* Patients have a previously implanted ILR, PMK, or ICD and are followed by daily automated remote transmissions
Study: NCT05677724

Intervention type: DIAGNOSTIC_TEST
Intervention: HBV DNA Sequencing
Description: Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.

Intervention type: DIAGNOSTIC_TEST
Intervention: HBV DNA Sequencing
Description: Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.

Intervention type: DIAGNOSTIC_TEST
Intervention: HBV DNA Sequencing
Description: Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.

Intervention type: DIAGNOSTIC_TEST
Intervention: HBV DNA Sequencing
Description: Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.

Intervention type: DIAGNOSTIC_TEST
Intervention: HBV DNA Sequencing
Description: Clinical surgical specimens were obtained, cleaned briefly and transported to the laboratory.~Single-cell suspension preparation and blood cell separation were performed, single-cell sorting suspension was prepared and put on the machine, sorting and library construction were performed, and mRNA sequencing adaptor was docked.~Single cell data analysis. Based on the findings of single cell analysis, functional verification tests of tumor immune microenvironment cell groups and functional changes of tumor cells were designed.
Study: NCT05803005

Intervention type: OTHER
Intervention: inflammatory marker in autism spectrum disorder
Description: Evaluate some Inflammatory markers \[IL-6, IL-8, TNF_alpha\] in children with autism spectrum disorder
Study: NCT05739955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sani24
Description: 24-hour continuously acting quaternary ammonium salt disinfectant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard EPA-registered disinfectant
Description: Standard EPA-registered disinfectant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Disinfection
Description: Routine disinfection at the study hospital
Study: NCT05861921

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture
Description: Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single-retainer Lithium Di-silicate Resin Bonded Fixed Partial Denture
Description: Lithium Di-silicate as final restorative material for resin bonded Fixed Partial Denture replacing missing upper anterior tooth.
Study: NCT05033860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Read leaflets containing knowledge of COVID-19 and vaccination.
Description: Leaflets containing knowledge of COVID-19 and vaccination were distributed, and participants are asked to read the leaflets.
Study: NCT06504043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST101
Description: Biological: HST101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HST101
Description: Biological: HST101
Study: NCT06298110

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelets Rich plasma of the same patient
Description: on the morning of surgery, 30 mL of venous blood will be drawn from the patient in anticoagulant-containing PRP tube for preparation of PRP solution. The drawn blood will be centrifuged at 1,200 rpm for 12 minutes to be separated into three layers: an upper layer that contains platelets and white blood cells, an intermediate thin layer (the buffy coat) that is rich in white blood cells, and a bottom layer that contains red blood cells. The upper and intermediate buffy layers will be transferred to an empty sterile tube. The plasma will be centrifuged again at 3,300 rpm for 7 minutes to help with the formation of soft pellets (erythrocytes and platelets) at the bottom of the tube. Pellets are homogenized in the lower third (5 mL) of the plasma to create the PRP. The prepared PRP solution will be transferred within sterile single use syringe (3cm) from the laboratory to the operation room, then applied and spread over the subcutaneous space before skin closure
Study: NCT05715034

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassionate Care
Description: Single-session web-based program

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxing with Nature
Description: Single-session web-based program
Study: NCT05388383

Intervention type: DEVICE
Intervention: Ti-robot
Description: Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital

Intervention type: DEVICE
Intervention: Ti-robot
Description: Tianji ROBOT--Orthopedic surgery robot led by Beijing Jishuitan Hospital
Study: NCT05312385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: Inhaled isoflurane administered by Sedaconda ACD-S

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous infusion of propofol
Study: NCT06279052

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone interview
Description: Phone interview during which the experience of the transition to adulthood among adolescents and young adults with Prader Willi Syndrome will be retrieved
Study: NCT05503368

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment of vitiligo using NCES
Description: NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment of vitiligo using NCES
Description: NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical treatment of vitiligo using NCES
Description: NCES is the standard technique for surgical treatment of vitiligo, herein we compare the standard technique, to added autologous cellular micro-grafts and to follicle cell suspension
Study: NCT04526444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker
Description: Fitness tracker Mi Smart Band 5 with the computational algorithm PAI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker
Description: Fitness tracker Mi Smart Band 5 with the computational algorithm PAI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitness tracker
Description: Fitness tracker Mi Smart Band 5 with the computational algorithm PAI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training
Description: Les Mills On Demand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online training
Description: Les Mills On Demand

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peer support via social media
Description: Facebook group
Study: NCT06290466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose group
Description: 300 mg,single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Low dose group
Description: 300 mg,single dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose group
Description: 400 mg, single dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: High dose group
Description: 400 mg, single dose.
Study: NCT05255991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered QID

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Treprostinil Ultrasonic Nebulizer
Description: Treprostinil ultrasonic nebulizer which emits a dose of approximately 6 mcg per breath.
Study: NCT05327127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K-877-ER
Description: K-877-ER tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSG452
Description: CSG452 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study: NCT04188067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE rTMS
Description: All study participants will receive one block of ACTIVE rTMS. Each block will consist of daily sessions of active rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SHAM rTMS
Description: All study participants will receive one block of SHAM rTMS. Each block will consist of daily sessions of SHAM rTMS delivered to the left dorsolateral prefrontal cortex over ten days (Monday through Friday).
Study: NCT06482099

Intervention type: BIOLOGICAL
Intervention: RSVpreF vaccine
Description: Injection in the muscle, 1 dose 0.5mL
Study: NCT06568003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Intervention
Description: Due to unsustainable effect of medical therapy and high risks of surgical treatment, transcatheter tricuspid valve intervention (TTVI) has been a major field of study in the world in the last 10 years. TTVI could potentially reduce TR with lower periprocedural risk and improve the patient's clinical status and prognosis. Per the ESC guidelines for surgical and interventional treatment of tricuspid regurgitation (2021 ESC/EACTS Guidelines for the Management of Valvular Heart Disease), Transcatheter intervention for symptomatic secondary severe TR may be considered in inoperable patients at a Heart Valve Centre with expertise in the treatment of tricuspid valve disease (Class IIb). 20 Transcatheter tricuspid treatment options can be divided into categories based on their mechanism of action: coaptation enhancement (edge-to-edge repair and spacer device), annuloplasty devices, caval valve implantation and valve replacement.
Study: NCT05636124

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kaneka i-ED coil
Description: The study device is the Kaneka i-ED coil T, FDA cleared under 510K number K192068. The coil is indicated for use in the endovascular embolization of intracranial aneurysms and other neurovascular abnormalities such as arteriovenous malformations and arteriovenous fistulae.
Study: NCT05052255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120
Description: RVU120 will be administered as a single oral dose every other day over a 3 week treatment cycle until disease progression or unacceptable toxicity and an alternative daily dosing schedule will also be tested.
Study: NCT05071300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplontersen
Description: Eplontersen will be administered by SC injection.
Study: NCT06372652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TE-8214 - SAD
Description: Cohort 1 - Single subcutaneous dose of 0.6 mg Cohort 2- Single subcutaneous dose of 1.2 mg Cohort 3 - Single subcutaneous dose of 2.0 mg Cohort 4 - Single subcutaneous dose of 3.0 mg or 4.0 mg Cohort 5 (Optional) - Single subcutaneous dose of 6.0 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single subcutaneous dose of matching placebo across the cohorts
Study: NCT05111002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: 600mg tablet orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: 600mg tablet orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: 100mg tablet orally twice daily
Study: NCT06539338

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INT2104
Description: INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INT2104
Description: INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INT2104
Description: INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: INT2104
Description: INT2104 is a lentiviral vector delivering a transgene for a chimeric antigen receptor specific for CD20 (CAR20)
Study: NCT05911243

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupressure Therapy
Description: Undergo auricular acupressure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive usual care
Study: NCT05466955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Free eye glasses for un or under-corrected myopia
Description: All participants randomised to the intervention group will be provided with free eye glasses
Study: NCT04819893

Intervention type: BIOLOGICAL
Intervention: Maternal blood sampling
Description: 5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols

Intervention type: BIOLOGICAL
Intervention: Maternal blood sampling
Description: 5 mL sample of venous blood on arrival at the maternity ward in accordance with standard protocols

Intervention type: BIOLOGICAL
Intervention: Umbilical cord blood sampling
Description: 0.5mL sample from the umbilical cord after childbirth standard protocols

Intervention type: BIOLOGICAL
Intervention: Umbilical cord blood sampling
Description: 0.5mL sample from the umbilical cord after childbirth standard protocols

Intervention type: BIOLOGICAL
Intervention: Placenta sampling
Description: Sampling of 3 cotyledons by cutting across the thickness of the placenta

Intervention type: BIOLOGICAL
Intervention: Placenta sampling
Description: Sampling of 3 cotyledons by cutting across the thickness of the placenta

Intervention type: OTHER
Intervention: Data collection
Description: Newborn, Maternal and Premature Retinopathy Screening Data Collection